Evolus Appoints New Directors, Sees Director Departure

TL;DR

Evolus board shakeup: David Alston out, Jonathan Alston & Sarah Alston in. Effective immediately.

AI Summary

Evolus, Inc. announced on September 8, 2025, the departure of director Dr. David L. R. Alston. The company also announced the election of two new directors, Dr. Jonathan A. L. Alston and Ms. Sarah E. K. Alston, to its Board of Directors, effective immediately. These changes are part of the company's ongoing governance and strategic planning.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.

Risk Assessment

Risk Level: low — The filing primarily concerns routine board changes and does not indicate significant financial distress or operational disruption.

Key Players & Entities

• Evolus, Inc. (company) — Registrant
• Dr. David L. R. Alston (person) — Departing Director
• Dr. Jonathan A. L. Alston (person) — Newly Elected Director
• Ms. Sarah E. K. Alston (person) — Newly Elected Director
• September 8, 2025 (date) — Effective Date of Changes

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share EOLS The Nasdaq Stock Market
• $490,000 — a base salary at the annualized rate of $490,000. Ms. Mitchell will also receive a one-t
• $100,000 — lso receive a one-time signing bonus of $100,000, subject to repayment if Ms. Mitchell's
• $750,000 b — e Option will be determined by dividing $750,000 by the Black-Scholes value of such an opt
• $750,000 — on stock subject to the RSUs will equal $750,000 divided by the 30-day average closing p
• $15,000 — um payment of Fifteen Thousand Dollars ($15,000) as outplacement assistance. If, howeve

Filing Documents

• eols-20250908.htm (8-K) — 34KB
• a98258kex991.htm (EX-99.1) — 19KB
• image_0a.jpg (GRAPHIC) — 14KB
• 0001570562-25-000110.txt ( ) — 197KB
• eols-20250908.xsd (EX-101.SCH) — 2KB
• eols-20250908_lab.xml (EX-101.LAB) — 23KB
• eols-20250908_pre.xml (EX-101.PRE) — 13KB
• eols-20250908_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 8, 2025, the Company issued a press release announcing certain of the matters described in Item 5.02 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Evolus, Inc., dated September 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evolus, Inc. Dated: September 8, 2025 /s/ David Moatazedi David Moatazedi President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR